Pilot Randomized Controlled Trial of IN FOCUS: A Mind‐Body Resiliency Intervention for Fear of Cancer Recurrence
Psycho-Oncology · 2024
DOI: 10.1002/pon.70026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psycho-Oncology, 2024. Verfasst von Daniel L Hall und 16 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Resilience, Psychological, Fear, Cancer Survivors, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Center for Biomedical Informatics and Information Technology, The Harvard Clinical and Translational Science Center, National Center for Advancing Translational Sciences, NCCIH NIH HHS.
Abstract (Originalsprache)
Introduction
Fear of cancer recurrence (FCR) is prevalent and distressing among survivors of cancer. Evidence‐based mind‐body and cognitive‐behavioral skills lack integration and testing in scalable formats.
Objective
This pilot randomized controlled trial (NCT04876599) tested a synchronous, virtual mind‐body group resiliency intervention for FCR (IN FOCUS).
Method
Adults with elevated FCR (FCR Inventory severity ≥ 16; 16–21 = elevated, 22–36 = clinically elevated) after completing primary treatment for non‐metastatic cancer were randomly assigned (1:1) to eight weekly sessions of IN FOCUS or usual care (UC; synchronous, virtual community group support referral). Feasibility metrics included ≥ 70% retention per arm (primary outcome), ≥ 75% attendance in ≥ 6 sessions, ≥ 75% adherence to relaxation skills practice ≥ 3 days per week and by delivery fidelity (% content covered in video‐recorded sessions). Acceptability was assessed quantitatively via ratings of enjoyableness, convenience, helpfulness, odds of future use, and satisfaction (benchmark ≥ 80% of ratings ≥ 4 on 1–5 Likert scale) and qualitatively via individual exit interviews. Linear mixed models explicated slopes in FCR (secondary) and resiliency (exploratory; Current Experiences Scale) from baseline to 2 months (primary endpoint) and 5 months using intention‐to‐treat.
Results
From July 2021 to March 2022, 64 survivors enrolled (25–73 years old, M = 7 years since diagnosis). IN FOCUS was feasible and acceptable (91% retention; attendance median = 7 sessions, 97% relaxation practice adherence, 95% content fully covered; 82% of acceptability ratings ≥ 4). Interviews ( n = 59) revealed benefits in both arms. By 2 months, compared to UC, IN FOCUS reduced FCR to a medium‐to‐large effect (Mdiff = −2.4; 95% CI = −4.2, −0.7; d = 0.66). By 5 months, FCR effects had attenuated (Mdiff = −0.16, 95% CI −1.97, 1.65; d = −0.04), although levels of resiliency had increased with a medium‐to‐large effect (Mdiff = 10.0; 95% CI = 4.9, 15.1; d = 0.78).
Conclusions
For survivors of non‐metastatic cancer, a synchronous, virtual mind‐body resiliency program for FCR is feasible, acceptable, and seemingly beneficial compared to a community group referral.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Förderung
- Center for Biomedical Informatics and Information Technology
- The Harvard Clinical and Translational Science Center, National Center for Advancing Translational Sciences
- NCCIH NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
- National Center for Complementary and Integrative Health
Zitieren
APA
Hall, D. L., Yeh, G. Y., O'Cleirigh, C., Wagner, L. I., Peppercorn, J., Denninger, J., Hirschberg, A. M., Lee, H., Markwart, M., Siefring, E., Mizrach, H. R., Li, R., Mian, Z., Tsuchiyose, E., Wen, A., Bullock, A. J., & Park, E. R. (2024). Pilot Randomized Controlled Trial of IN FOCUS: A Mind‐Body Resiliency Intervention for Fear of Cancer Recurrence. Psycho-Oncology. https://doi.org/10.1002/pon.70026
Vancouver
Hall DL, Yeh GY, O'Cleirigh C, Wagner LI, Peppercorn J, Denninger J, et al. Pilot Randomized Controlled Trial of IN FOCUS: A Mind‐Body Resiliency Intervention for Fear of Cancer Recurrence. Psycho-Oncology. 2024. doi:10.1002/pon.70026
BibTeX
@article{Hall2024,
author = {Hall, Daniel L and Yeh, Gloria Y and O'Cleirigh, Conall and Wagner, Lynne I and Peppercorn, Jeffrey and Denninger, John and Hirschberg, April M and Lee, Hang and Markwart, Michaela and Siefring, Emma and Mizrach, Helen R and Li, Raissa and Mian, Zainab and Tsuchiyose, Erika and Wen, Angela and Bullock, Andrea J and Park, Elyse R},
title = {Pilot Randomized Controlled Trial of IN FOCUS: A Mind‐Body Resiliency Intervention for Fear of Cancer Recurrence},
journal = {Psycho-Oncology},
year = {2024},
doi = {10.1002/pon.70026}
}
EUVIMED